Aminex Therapeutics raises $10M ( $19M total) and launches Phase I trial of AMXT‑1501 for solid tumors; first patient dosed
Aminex Therapeutics raised $10 million, bringing its total funding to $19 million, and has begun a Phase I clinical trial of its small-molecule immunotherapy AMXT‑1501 for multiple solid tumors, with the first patient dosed in San Antonio.